MIAMI, February 4, 2026 — Leads & Copy — Defiance ETFs has launched the Defiance Daily Target 2X Long MRNA ETF (MRNX), the company said today.
The new fund expands Defiance ETFs’ lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to biotechnology and life sciences companies.
The MRNX fund seeks to deliver 200% of the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). It is designed for traders seeking magnified, short-term bullish exposure to Moderna, Inc., a biotechnology company known for its messenger RNA (mRNA)–based medicines and vaccine development platform, the company said.
The fund seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). The fund does not seek to achieve its stated investment objective for a period other than a single trading day.
Moderna, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines based on messenger RNA technology. The company’s platform enables the design of mRNA-based therapeutics and vaccines across a range of disease areas, including infectious diseases and other unmet medical needs. Moderna, Inc. is listed on the Nasdaq Stock Market and is classified within the biotechnology industry.
An investment in the ETF is not a direct investment in Moderna, Inc.
Defiance ETFs LLC is the ETF sponsor. Tidal Investments, LLC is the fund’s investment adviser.
Investing involves risk, and principal loss is possible. As an ETF, the fund may trade at a premium or discount to NAV. Shares are bought and sold at market price and are not individually redeemed from the fund. A portfolio concentrated in a single issuer may be subject to a higher degree of risk.
The fund is not suitable for all investors and is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently. The fund is not intended to be used by investors who do not intend to actively monitor and manage their portfolios. The fund pursues daily leveraged investment objectives, which means it is riskier than alternatives that do not use leverage. The fund magnifies the performance of the Underlying Security and is designed strictly for short-term use.
For periods longer than a single day, the fund’s performance will be the result of compounded daily returns, which is very likely to differ from 200% of the return of MRNA over the same period. Investors could lose their entire principal within a single trading day.
The market value of Moderna, Inc. may decline if the company fails to meet its business or clinical development expectations, experiences setbacks in research or regulatory approvals, faces competitive pressures in the biotechnology industry, or is impacted by broader market, economic, or healthcare policy developments. Adverse developments specific to Moderna, Inc. or the biotechnology sector could negatively impact the Fund’s performance.
The fund’s value may fluctuate more sharply in response to events affecting Moderna, Inc. than funds that invest in a broader range of issuers.
There is no guarantee that the fund will achieve a high degree of correlation with 200% of the daily performance of Moderna, Inc. Market disruptions, extreme volatility, liquidity constraints, or limitations in the availability of derivatives may cause the fund’s performance to deviate from its daily leveraged investment objective.
The fund’s use of swap agreements and options contracts involves risks different from those associated with direct investments in securities. If a counterparty to a swap agreement or other derivative instrument fails to meet its contractual obligations, the fund may experience losses. Daily rebalancing of the fund’s holdings is expected to result in high portfolio turnover, which may increase transaction costs and potentially result in higher taxable distributions for shareholders.
The fund is recently organized and has a limited operating history. As a result, there is limited performance history upon which investors can evaluate the fund’s ability to achieve its investment objective.
Diversification does not ensure a profit nor protect against loss in a declining market. Brokerage commissions may be charged on trades.
Distributed by Foreside Fund Services, LLC.
Source: Defiance ETFs
